WO2019147877A1 - Procédés et compositions pour réduire la sensation de sécheresse vaginale - Google Patents

Procédés et compositions pour réduire la sensation de sécheresse vaginale Download PDF

Info

Publication number
WO2019147877A1
WO2019147877A1 PCT/US2019/015051 US2019015051W WO2019147877A1 WO 2019147877 A1 WO2019147877 A1 WO 2019147877A1 US 2019015051 W US2019015051 W US 2019015051W WO 2019147877 A1 WO2019147877 A1 WO 2019147877A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaginal
care composition
vaginal care
applicator
preservative
Prior art date
Application number
PCT/US2019/015051
Other languages
English (en)
Inventor
Samantha Chen-Yee WANG
Larry Richard Robinson
Maria A. FRIBERG
Scott Brian BINTRIM
Nery Vanesa BRESLIN
Kyra L. WILSONHOUCK
Raphael Warren
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to EP19706817.4A priority Critical patent/EP3743044A1/fr
Priority to CN201980009752.5A priority patent/CN111655232A/zh
Publication of WO2019147877A1 publication Critical patent/WO2019147877A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Definitions

  • Described herein are methods and compositions for reducing the feeling of vaginal dryness.
  • Menopause is generally defined as 12 months after a woman’s last menstrual period.
  • the process leading to menopause can be a gradual process, however.
  • peri-menopause and menopause can be accompanied by hot flashes, night sweats, mood changes, stress, fatigue, irritability, and difficulty with memory.
  • menopause is associated with a decrease in estrogen production.
  • Decreased estrogen blood levels can result in changes to both the internal and external genitalia (i.e., vulvar- vaginal region), including vaginal atrophy and a thinning of the vaginal and urethral mucous membrane, a loss in vaginal elasticity, and a reduction in gland secretion, which may be accompanied by a decrease in tissue hydration.
  • vaginal atrophy can facilitate urogenital infections and may also result in vaginal irritation, burning, dryness, itching, odor, and pain during sexual intercourse (dyspareunia), thus greatly impacting a woman’s quality of life.
  • hormone replacement therapy can include an estrogen supplement with or without progesterone that is administered deep within the vaginal canal. While hormone therapies have shown positive effects in the treatment of vaginal atrophy, some women continue to experience menopausal symptoms, and for many women, such treatment can prove to be too expensive. Hormone replacement therapy is generally limited by consumer fear and by contraindications such as a history of cancer and thromboembolism. Moreover, due to the nature of the condition, women may feel uncomfortable and/or embarrassed discussing the above-described symptoms and may avoid seeking a doctor’s consultation.
  • vaginal dryness Current over-the-counter approaches to relieving vaginal dryness include the application of sexual lubricants for reducing discomfort during intimacy (e.g., Replens® Silky Smooth Personal Lubricant, Astroglide®, K-Y ® gels and lubricants) or vaginal moisturizers (e.g., Replens® Long Lasting Moisturizer and Replens® Moisture Restore External Comfort Gel, or HyaloGyn/HyaloFemme, available from Fidia Farmaceutici SpA and both supplied with disposable applicators to place in the vaginal canal).
  • sexual lubricants for reducing discomfort during intimacy
  • vaginal moisturizers e.g., Replens® Long Lasting Moisturizer and Replens® Moisture Restore External Comfort Gel, or HyaloGyn/HyaloFemme, available from Fidia Farmaceutici SpA and both supplied with disposable applicators to place in the vaginal canal.
  • moisturizers generally rehydrate dry vaginal epithelial tissue and are absorbed into the epithelia, but do not provide a desired lubricity.
  • current vaginal moisturizer products include mucoadhesive polymers that bind to, and hold water at, the vaginal epithelial surface in order to hydrate the underlying cells and are formulated to be applied deep within the vaginal canal.
  • Such application regimens typically involve depositing 3 to 6g of the vaginal moisturizer product deep within the vaginal canal every 3 days.
  • application of a vaginal product at this dosing regimen does not lend itself to easy habit adoption.
  • the large quantity of product administered with each dose can result in leakage of the product from the vaginal canal, which can be undesirable and embarrassing to consumers and can impact the efficacy and desired use of the product.
  • the plunger-type devices for delivering such products deep within the vaginal canal may also be an added mechanical irritant and may compromise the fragile tissue.
  • tissue deep within the vaginal canal lacks the sensitivity /innervation of the vaginal introitus/vulva and can primarily only detect“pressure” and not other sensations. As a result, the user may not feel any soothing benefits during or after application deep within the vaginal canal. Without being limited by theory, it is believed that applying a vaginal composition to the introitus and/or external vaginal tissue, which has the highest sensitivity and exhibits the most signs of atrophy, may provide greater relief from symptoms.
  • Sexual lubricants act to provide fast acting, short-term relief from vaginal dryness and related pain during sex.
  • water and silicone based lubricants are designed to be applied shortly before sexual activity, which can impact the overall experience and hinder spontaneity, and may not provide long-lasting benefits because they are typically wiped or washed off after use.
  • typical sexual lubricants have a low viscosity, making them difficult to apply to the desired location and tend to leak from the site of application.
  • Silicone- based lubricants are also known to stain fabrics, which can be undesirable to consumers, and may not be compatible with silicone vaginal applicators or devices.
  • vaginal atrophy and dryness can cause pain and discomfort during sex
  • vaginal atrophy can also cause discomfort and pain during everyday activities such as walking, exercising, or sitting/standing.
  • Women suffering from vaginal atrophy have reported experiencing vaginal dryness that can cause the vaginal tissue to stick together and/or to clothing, which can be uncomfortable and/or painful and can hinder daily activities.
  • Women experiencing vaginal atrophy are also limited in what kinds of clothing they can wear; even jeans or tighter pants can cause pain and discomfort.
  • a method of reducing the feeling of vaginal dryness comprises: (a) a female user providing an amount of a vaginal care composition on at least a portion of the outer surface of an applicator; and (b) administering at least a portion of the amount of the vaginal care composition to her vaginal introitus and, optionally, one or more of her vulva, vestibule, labia majora, labia minora, or external urogenital tract while grasping and manipulating the applicator; wherein the vaginal care composition comprises an oil-in-water emulsion and a thickener comprising a polyacrylamide polymer and a fatty alcohol.
  • a method of restoring vaginal moisture and lubrication comprises administering a vaginal care composition to the vaginal introitus of a female user in need thereof; wherein the vaginal care composition comprises: (a) an oil-in- water emulsion; (b) a thickener comprising a polyacrylamide polymer; and (c) hyaluronic acid or a salt thereof; wherein the vaginal care composition has a viscosity of from about 20,000 cps to about 200,000 cps.
  • a kit for reducing the feeling of vaginal dryness comprises: a vaginal care composition and an applicator for applying the vaginal care composition to a vaginal introitus and, optionally, external vaginal tissues; wherein the vaginal care composition comprises an oil-in- water emulsion and a thickener comprising a polyacrylamide polymer and a fatty alcohol.
  • a method of reducing the feeling of vaginal dryness comprises: (a) a female user providing an amount of a vaginal care composition on at least a portion of an applicator; and (b) administering at least a portion of the amount of the vaginal care composition to her vaginal area while grasping and manipulating the applicator; wherein the vaginal care composition comprises an oil-in- water emulsion and a thickener comprising a polyacrylamide polymer and a fatty alcohol.
  • FIG. 1 is a front view of one example of a kit, including a pouch, a dispenser for a vaginal care composition, and an applicator;
  • FIG. 2 is a perspective top view of the applicator of FIG. 1;
  • FIG. 3 is a front view of the applicator of FIG. 1 resting upright on a surface.
  • vaginal dryness Consumers are looking for improved ways to reduce the feeling of vaginal dryness that can provide long-lasting moisturizing and lubricity benefits using a once-a-day application regimen with a product having a non-sticky texture, without the need for conventional sexual lubricants that are used each time symptoms or discomfort is felt.
  • rheology modifiers e.g. carbomers and carbopols
  • mucoadhesives to increase the viscosity of the product and to hold water at the epithelial surface.
  • mucoadhesive rheology modifiers derive their adhesive properties from an abundance of - COOH, salts of -COOH, and -OH moieties that hydrogen bond to mucosal tissue, and the mostly linear, flexible backbone of the polymers maximize the interaction between the hydrogen bonding groups and mucosal tissue.
  • rheology modifiers are often comprised of acrylate and/or methacrylate monomers, which can create salts of -COOH when the polymer undergoes hydrolysis and can further increase the mucoadhesive nature of the polymer.
  • mucoadhesive polymers have been reported by female users to feel sticky when used in a vaginal product, which can be undesirable. Such texture properties can be unacceptable to some consumers, resulting in decreased dosing compliance or the avoidance of vaginal products altogether.
  • Hyaluronic acid is a natural lubricating and moisturizing substance found in the skin and around joints, and is widely used in skincare and medical products due to its biocompatibility, hydrating, and mucoadhesive properties.
  • commercially available hyaluronic acid can undergo significant degradation in acidic environments, in particular at body temperature (about 37 °C). This degradation leads to a reduction in the molecular weight of the hyaluronic acid and a corresponding decrease in its viscosity. Accordingly, the lubricating effects of hyaluronic acid can be generally short in duration.
  • hyaluronic acid vaginal lubricants can degrade upon storage, leading to a limited shelf-life.
  • increasing the concentration of hyaluronic acid can result in poor texture properties and can increase the cost of the product.
  • vaginal care composition comprising an oil-in-water emulsion, hyaluronic acid or salt thereof, and a non-mucoadhesive thickener can maintain a sufficient viscosity even at acidic pH and temperature conditions of the vaginal environment while still providing long-lasting moisture and lubrication without being sticky.
  • vaginal care composition comprising an oil-in-water emulsion, hyaluronic acid or salt thereof, and a thickener comprising a polyacrylamide polymer can be applied daily to the vaginal introitus and, optionally, the external vaginal tissue to provide a feeling of moisturization and lubricity that lasts throughout the day, even after wiping and/or urination, thus making every day activities more comfortable.
  • polyacrylamide polymers are non-mucoadhesive because they are substantially free of -COOH, salts of -COOH, and -OH moieties and are cross-linked using a monomer with two or more vinyl moieties.
  • the cross-linking agent can restrict the conformational flexibility of the polymer and reduce the possible conformations that interact with mucosal tissue.
  • acrylamide monomers are less prone to hydrolysis, and if they do undergo hydrolysis, will create primary amine groups that are not prone to interacting with mucosal tissue.
  • the thickener can further comprise a fatty alcohol that can create a lamellar gel network which can thicken the formulation without being mucoadhesive. It is believed that the fatty alcohols can create asymmetric structures that can bind water and build rheology.
  • vaginal care composition described herein can have sufficient viscosity to allow for application to the body without making a mess (i.e. it can stay on an applicator/finger during application without dripping), but can also shear and melt upon application so that is spreads smoothly on the body.
  • the oil-in-water emulsion enables the formula to have both emollients in the oil phase as well as water-soluble vaginal care agents in the same formula, which can provide acute moisturization and chronic healing.
  • the combination of having an aesthetically pleasing acute feeling (smooth application) encourages daily use, which can be important for the chronic healing to take place, in particular at the introitus/vulva which has the highest sensitivity/innervation.
  • vaginal care composition comprising an oil-in-water emulsion, hyaluronic acid or salt thereof, and a thickener comprising a polyacrylamide polymer that can be applied to the vaginal introitus and, optionally, one or more of the vulva, vestibule, labia majora, labia minora, and/or external urogenital tract to reduce the feeling of vaginal dryness.
  • the vaginal care composition can provide relief of vaginal dryness for about 3 hours to about 48 hours, alternatively for about 4 hours to about 40 hours, alternatively for about 6 hours to about 36 hours, alternatively for about 12 hours to about 24 hours.
  • a kit comprising a vaginal care composition and a delivery device, such as an applicator, for applying the vaginal care composition.
  • compositions of the disclosure can comprise, consist essentially of, or consist of, the components as well as optional ingredients described herein.
  • consisting essentially of means that the applicator, composition, or component may include additional ingredients or features, but only if the additional ingredients or features do not materially alter the basic and novel characteristics of the claimed applicators, compositions, or methods.
  • the singular forms“a,”“an,” and“the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
  • aromatic alcohol preservative includes molecules that contain at least one benzyl moiety, a single hydroxyl moiety, and is free of carboxylates.
  • the hydroxyl moiety may be directly bonded to the benzyl moiety or on a side chain.
  • estrogen agent means any natural or synthetic estrogen hormone (e.g., estrone, estradiol and estriol), metabolites thereof, esters thereof, analogues thereof, phytoestrogens (e.g., isoflavones, coumestans, prenylflavonoids), estrogen precursors (e.g., dehydroepiandrosterone) and/or any compound which binds to an estrogen receptor or which otherwise exhibits at least mild or weak estrogen-like effects, including selective estrogen receptor modulators (“SERM”) such as, for example: afimoxifene (4-hydroxy tamoxifen), arzoxifene, apeledoxifene, clomifene, femarelle (DT56a), lasofoxifene, ormeloxifene, raloxifene, tamoxifen, toremifene, mifepristone (RU486), VA2914, ulipristal, Proellex
  • SERM selective estrogen
  • introduction means the vaginal opening in a human that extends from the entrance of the vaginal canal to 35 millimeters (mm) into the vaginal canal.
  • preservative enhancing agent means any molecule that is not registered for use in cosmetic compositions with the appropriate regulatory body as a preservative but demonstrates improved anti-bacterial, anti-microbial, or anti-fungal benefits when included in an oil-in- water vaginal care composition.
  • mucoadhesive refers to the phenomenon where a natural or synthetic substance applied to a mucosal epithelium, adheres, usually creating a new interface, to the mucus layer. Generally, mucoadhesion can be achieved via physical or chemical processes or both.
  • peripheral woman is one who in the absence of hormone replacement therapy or other medication would experience a change in her intermenstrual cycle interval and have associated symptoms of estrogen deficiency, such as vasomotor flushes, vaginal dryness and/or worsening premenstrual syndrome. Also included are women who in the absence of hormone replacement therapy or other medication would experience less than 12 months amenorrhea.
  • pharmacologically effective amount means the amount of a composition, or ingredient thereof, effective to produce the intended pharmacological, therapeutic or preventive result.
  • progesterone agent means any natural or synthetic progesterone hormone, metabolites thereof, analogues thereof, progesterone precursors and/or any compound which binds to a progesterone receptor or which otherwise exhibits at least mild or weak progesterone-like effects, including selective progesterone receptor modulators (“SPRM”) such as, for example, telapristone.
  • SPRM selective progesterone receptor modulators
  • rotational symmetry means the applicator, or a portion thereof such as the insertion portion or the grippable portion, has an overall shape that looks the same thru some rotation (e.g., 45°, 90°, 135°, 180°, 225°, 270°, 315°, or 360°) about its longitudinal axis.
  • some rotation e.g. 45°, 90°, 135°, 180°, 225°, 270°, 315°, or 360°
  • an applicator that has an overall shape that looks the same thru a rotation of 45° is considered rotationally symmetrical thru that 45° rotation.
  • an applicator that has an overall shape that looks the same thru one full rotation is considered rotationally symmetrical thru 360°.
  • the reference to rotational symmetry herein unless stated otherwise, ignores surface features such as print, coloring, coatings, text, graphics, dosing indicators, insertion indicators, surface textures, and surface finishes.
  • substantially free means a component or materialis present in amount less than about 0.1%, 0.05%, 0.025%, 0.01%, or 0.001% by weight of the vaginal care composition.
  • tapeer means to become smaller toward one end.
  • An applicator, or feature thereof such as the insertion portion may have a taper that is gradual, substantial, intermittent, continuous and combinations thereof.
  • an applicator is considered to taper from the maximum width to the tip merely if the bulk cross-sectional area (e.g., inclusive of both solid cross-sectional area and void cross-sectional area) at the tip is less than the bulk cross-sectional area at the maximum width, even though, for example, the bulk cross-sectional area may intermittently increase or remain constant between the maximum width and the tip.
  • the bulk cross-sectional area e.g., inclusive of both solid cross-sectional area and void cross-sectional area
  • treating means relieving or alleviating.
  • vaginal area means the vaginal canal and the vulva (or pudendum), a collective term for the external female genital organs that are visible in the perineal area including the vaginal orifice, vaginal introitus, vulvar vestibule, labia majora, labia minora, external urogenital tract, urethral orifice, clitoris, and vulvar skin which is bounded longitudinally by the mons pubis and anus and bounded laterally by the genitocrucal folds.
  • vaginal canal refers to the tissue proximal to the vaginal introitus.
  • vaginal care composition means any composition that is suitable for application to the vaginal introitus and/or one or more of the vulva, vestibule, labia majora, labia minora, and/or external urogenital tract and which is useful for treating or ameliorating vaginal dryness.
  • the vaginal care compositions described herein are suitable for application to the vaginal introitus and, optionally, the external vaginal tissues.
  • the vaginal care composition is preferably non-irritating and substantially free of ingredients that are less suitable for application to these tissues.
  • the vaginal care composition may comprise a preservative system comprising one or more preservatives and a preservative enhancing agent.
  • a preservative can be understood to be a chemical or natural compound (or combination of compounds) that can help inhibit the growth of microbes, thus protecting the consumer during intended product use and/or increasing the shelf-life of the composition.
  • the preservative(s) can be non irritating when applied to the vaginal introitus/vulvar vestibule.
  • the preservative(s) can be selected from the group consisting of aromatic alcohol preservatives, organic acid preservatives, salts thereof, and combinations thereof.
  • Organic acid preservatives are organic molecules with at least one carboxyl group.
  • the organic acid preservatives can be soluble in water and can have a water solubility at ambient conditions of at least 0.1, alternatively at least 0.5, alternatively at least 1 g / 100 ml water.
  • Non- limiting examples of organic acid preservatives can include glutamic acid, malonic acid, phthalic acid, fumaric acid, formic acid, malic acid, heptanoic acid, ascorbic acid, oxalic acid, succinic acid, glutaric acid, adipic acid, propionic acid, butyric acid, pentanoic acid, hexanoic acid, pimelic acid, suberic acid, acetic acid, carbonic acid, lactic acid, salicylic acid, benzoic acid, sorbic acid, citric acid, 4-hydroxybenzoic acid, dehydroacetic acid, undecylenic acid, salts thereof, and mixtures thereof.
  • Salts of the organic acid preservative may include any cationic counterion.
  • Non-limiting examples of organic acid preservative salt counter ions can include sodium, ammonium, calcium, magnesium, potassium, and silver.
  • the organic acid preservative can be selected from the group consisting of salicylic acid, benzoic acid, sorbic acid, citric acid, propionic acid, 4-hydroxybenzoic acid, dehydroacetic acid, formic acid, undecylenic acid, salts thereof, and mixtures thereof.
  • the organic acid preservative can be selected from the group consisting of benzoic acid, sodium benzoate, citric acid, sodium citrate, sodium salicylate, salicylic acid, sorbic acid, and mixtures thereof.
  • a combination of an acid and a salt of the same organic acid preservative such as citric acid and sodium citrate
  • a combination of two or more organic acid preservatives such as citric acid, sodium citrate, and sodium benzoate, can be used.
  • citric acid, sodium citrate, and sodium benzoate can be used.
  • the preservative can be an aromatic alcohol preservative.
  • aromatic alcohol preservatives can include biphenyl-2-ol, butyl 4-hydroxybenzoate, propyl 4- hydroxybenzoate, ethyl 4-hydroxybenzoate, methyl 4-hydroxybenzoate, triclosan, chloroxylenol, o-cymen-5-ol, chlorophene, dichlorobenzyl alcohol, phenoxyethanol, benzyl alcohol, phenoxyisopropanol, benzylhemiformal, and combinations thereof.
  • the aromatic alcohol preservative can be selected from the group consisting of benzyl alcohol, phenoxyethanol, propyl 4-hydroxybenzoate, ethyl 4-hydroxybenzoate, and combinations thereof.
  • the vaginal care composition can comprise less than about 3% of a preservative, alternatively less than about 2%, alternatively less than about 1.8%, alternatively less than about 1.6%, all by weight of the vaginal care composition.
  • the vaginal care composition can comprise from about 0.1% to about 3% of a preservative, alternatively from about 0.5% to about 2%, alternatively from about 1.2% to about 1.6%, all by weight of the vaginal care composition.
  • the vaginal care composition can comprise less than about 3% of a preservative system, alternatively less than about 2%, alternatively less than about 1.8%, alternatively less than about 1.6%, all by weight of the vaginal care composition.
  • the vaginal care composition can comprise from about 0.1% to about 3% of a preservative system, alternatively from about 0.5% to about 2%, alternatively from about 1.2% to about 1.6%, all by weight of the vaginal care composition.
  • the vaginal care composition can comprise a preservative enhancing agent.
  • the preservative enhancing agent can comprise sorbitan caprylate.
  • the preservative enhancing agent can consist essentially of sorbitan caprylate.
  • An exemplary sorbitan caprylate is manufactured by Clariant (Muttenz, Switzerland) under the designation VELSAN® SC.
  • the vaginal care composition can comprise from about 0.01% to about 3% preservative enhancing agent, alternatively from about 0.01% to about 1%, alternatively from about 0.05% to about 0.8%, alternatively from about 0.1% to about 0.3%, all by weight of the vaginal care composition.
  • the preservative enhancing agent can be substantially free of diols. Without being limited by theory, it is believed that diols at some levels can be irritating to the vaginal area, in particular the vaginal introitus.
  • the preservative system may also include additional compounds, for example chelating agents, such as ethylenediamine tetraacetic acid (EDTA) and its salts, or diethylene triamine pentaacetic acid (DTP A) and its salts.
  • chelating agents such as ethylenediamine tetraacetic acid (EDTA) and its salts, or diethylene triamine pentaacetic acid (DTP A) and its salts.
  • the vaginal care composition has a pH from about 4.0 to about 5.5, preferably from about 4.3 to about 5.0, more preferably 4.4 to about 4.8.
  • a pH in this range is that the pH of the vaginal care composition will be close to the pH of the vaginal introitus. It is believed that if the pH is lower than this range the composition may be irritation to the vaginal introitus/ external vaginal tissues. It is believed that if the pH is above this range, the preservative system may not be as effective and higher levels of the preservative system and/or additional preservatives may be needed to prevent microbial growth.
  • the vaginal care composition may be provided, for example, in the form of a spreadable gel, serum, lotion, paste, or cream.
  • the vaginal care composition can be in the form of an oil-in-water emulsion.
  • An oil-in-water emulsion may provide a sensorial feel that is light and non-greasy, but still delivers moisturization and lubricity without aesthetic negatives like stickiness or heavy residue commonly associated with oil-based compositions and/or mucoadhesive ingredients.
  • the vaginal care compositions may further comprise one or more vaginal care agents.
  • the vaginal care composition may comprise one or more water soluble ingredients.
  • the vaginal care composition can comprise water, one or more oils, and, optionally, one or more vitamins and/or pro- vitamins (e.g., a substance that may be converted to a vitamin by metabolic processes), one or more thickeners, one or more emulsifiers, one or more humectants, one or more lubricants (which may also be in the form of an oil), one or more moisturizers (which may also be in the form of an oil), one or more feel modifiers (e.g., particulates, powders and film forming agents).
  • the vaginal care composition preferably provides a suitable viscosity, dry feel, moisturization/emolliency benefits, suitable lubricity, and/or vaginal health benefits.
  • the vaginal care composition may comprise water in an amount greater than about 50%, or greater than about 60%, or from about 50% to about 95%, or from about 60% to about 90%, or from about 65% to about 80%, all by weight of the vaginal care composition.
  • the water may provide a carrier for water soluble ingredients as well as a moisturization benefit.
  • the vaginal care composition may comprise one or more emollients.
  • An emollient can help skin maintain a soft, smooth appearance.
  • Emollients can be deposited onto the skin and remain at its surface as a thin protective layer, providing moisturizing and/or lubricating benefits.
  • Non-limiting examples of emollients can include botanical oils, hydrocarbon oils, fatty acids, esters of monobasic and/or dibasic and/or tribasic and/or polybasic carboxylic acids with mono and polyhydric alcohols, polyoxyethylenes, polyoxypropylenes, mixtures of polyoxyethylene and polyoxypropylene ethers of fatty alcohols, and mixtures thereof.
  • the vaginal care composition may comprise less than about 30%, alternatively from about 1% to about 20%, alternatively from about 5% to about 15%, alternatively from about 10% to about 15% emollient, all by weight of the vaginal care composition.
  • the vaginal care composition can comprise from about 0.05% to about 5% emollient, or from about 0.1% to about 2%, or from about 0.2% to about 1%, by weight of the vaginal care composition.
  • the botanical oil can be derived from one or more plant source materials, such as the leaf, root, bark, stem, flower, or seed of a plant.
  • the botanical oil may be a seed oil, a nut oil, a flower oil, or a leaf oil.
  • the botanical oil may comprise polyunsaturated fatty acids, preferably omega-3 (e.g., a-linolenic acid) and/or omega-6 fatty acids.
  • the botanical oil may be a coconut oil, an evening primrose oil, a sunflower seed oil, a safflower oil, and combinations thereof, which contain omega-3 and/or omega-6 fatty acids.
  • suitable botanical oil materials can include oleic canola Oil (Brassica campestris, B.
  • the vaginal care composition may comprise from about 0.05% to about 5% of botanical oil(s), or from about 0.1% to about 2%, or from about 0.2% to about 1%, by weight of the vaginal care composition.
  • the vaginal care composition may further comprise one or more silicone oils.
  • Silicone oils are liquids comprising one or more polymerized siloxanes or silicone polymers (e.g., polysiloxanes, polydimethylsiloxanes (PDMS) and combinations thereof).
  • the silicone oil may comprise dimethicone, dimethiconol (a high molecular weight silicone gum), and combinations thereof, one example being Dow Corning® 1503 Fluid (available from Dow Coming Corp.) which comprises a combination of dimethicone and dimethiconol.
  • the vaginal care composition may comprise from about 0.1% to about 4% silicone oil(s), alternatively from about 0.5% to about 3%, alternatively from about 1% to about 3%, all by weight of the vaginal care composition.
  • One advantage to including a silicone oil is that it can provide a lubrication benefit. This can be important because a silicone oil can impart an acute benefit during sexual intercourse, which could be painful without a lubricating component. A silicone oil can also impart an acute benefit during and after application; the lubrication benefit allows the product to glide and spread easily during application and lubricates the vaginal tissue during daily activities.
  • the vaginal care composition may comprise one or more vaginal care agents for providing a vaginal health benefit.
  • Vaginal care agents can include vitamins, pro- vitamins, and combinations thereof.
  • Non-limiting examples of vaginal care agents can niacinamide, panthenol, vitamin B3, vitamin B5, vitamin E and derivatives thereof.
  • the vaginal care agent is selected from the group consisting of niacinamide, panthenol, and combinations thereof.
  • the vaginal care composition may comprise from about 0.1% to about 7%, or from about 0.5% to about 6%, or from about 2% to about 5% by weight of the vaginal care composition of vitamin(s) and/or pro-vitamin(s).
  • the vaginal care composition may comprise one or more humectants, such as glycerol.
  • the humectant may be provided in an amount from about 0.1% to about 20%, or from about 1% to about 15%, or from about 8% to about 12%, all by weight of the vaginal care composition.
  • the humectant can be provided in an amount from about 0.1% to about 5%, alternatively from about 0.5% to about 1%, all by weight of the vaginal care composition.
  • Other humectants which may be provided include other polyhydroxy alcohols, polyethylene glycols, aloe vera in any of its forms, hyaluronic acid or salts thereof, and combinations thereof.
  • the humectants may provide a moisturizing benefit.
  • the vaginal care composition can comprise from about 0.1% to about 2% hyaluronic acid or a salt thereof, alternatively from about 0.3% to about 1%, all by weight of the vaginal care composition. It was previously believed that hyaluronic acid or a salt thereof at levels higher than about 0.1% in a skin care composition can leave an undesirable sticky residue on the skin. However, it was surprisingly found that hyaluronic acid or a salt thereof could be used in a vaginal care composition at a level of greater than about 0.1% without feeling sticky.
  • the hyaluronic acid or salt thereof can have a weight average molecular weight of from about 0.5-1.3 megadalton (Mda), alternatively from about 0.75 to about 1 Mda.
  • the vaginal care composition may further comprise one or more silicone particles to impart desirable feel characteristics to the vaginal care composition.
  • the vaginal care composition can comprise siloxane particles (e.g., polymethylsilsesquioxane) having an average particle size from about lpm to about l5pm, alternatively from about 2 pm to about 10 mhi, alternatively from about 4 mhi to about 8 mhi.
  • the particles may be in the form of mono-disperse microspheres.
  • the polymethylsilsesquioxane particles are sometimes also referred to as silicone resins.
  • Some non-limiting examples of polymethylsilsesquioxane particles can include TOSPEARL® series from Momentive Performance Materials, Inc.
  • the vaginal care composition can comprise from about 0.01% to about 3% silicone particles, alternatively from about 0.1% to about 1.25%, alternatively from about 0.2% to about 0.75%, all by weight of the vaginal care composition.
  • the vaginal care composition may further comprise a silicone wax.
  • Silicone waxes are materials that contain at least one silicon atom which are solid or semisolid at room temperature.
  • the silicone wax can have a melting temperature ranging from about 24°C to about l05°C, alternatively from about 25°C to about 40°C, alternatively from about 28 °C to 35°C.
  • the melting temperature of the silicone wax can be measured according to the drop melting point method of ASTM D127 (January 1, 2015).
  • the silicone was can be an organopolysiloxane having the following formula (I):
  • Rci, Rn, and R12 are, independently of one another, chosen from a (C1-C30) alkyl moiety, a (C1-C30) alkoxy moiety, and a (C6-C30) aryl moiety,
  • Rio is chosen from a (C2-C36) alkyl moiety, a (C2-C36) alkoxy moiety, a (C2-C36) alkyl moiety, and a (C2-C36) alkoxy moiety which is substituted by an ester group, it also being possible for Rio to be a methyl moiety when Z is a (C2-C30) alkyl moiety, a (C2-C30) alkoxy moiety, and a (C2-C30) ester, Z is chosen from a (C1-C30) alkyl moiety, a (C1-C30) alkoxy moiety, a (C6-C30) aryl moiety, and a (C1-C30) ester,
  • u is 0 or an integer between 1 and 100
  • v is an integer between 3 and 100.
  • Non-limiting examples of suitable silicone waxes can include ABIL® Wax series of alkyl silicones from Evonik Industries AG (Essen, Germany), including ABIL® Wax 2434 (stearoxy dimethicone), ABIL® Wax 2440 (behenoxy dimethicone), and ABIL® Wax 9810P (C24-28 alkyl dimethicone).
  • silicone waxes include Dow Coming® 2503 Wax (stearyl dimethicone and octadecene), Dow Coming® SW-8005 C30 Resin Wax (C30-45 alkyldimethylsilyl polypropylsilsesquioxane), and Dow Coming® 580 Wax (Stearoxy trimethylsilane and stearyl alcohol) all from Dow Coming Corp. (Carrollton, KY), VP 1622 (stearoxy dimethicone) from Wacker Chemie AG (Munich, Germany).
  • Preferred silicone waxes include semisolid waxes such as Silwax® L118 (stearyl dimethicone) available from Siltech (Toronto, Ontario, Canada) with a melting temperature of about 30°C.
  • the vaginal care composition can comprise from about 0% to about 20% silicone wax, alternatively from about 0.1% to about 10%, alternatively from about 0.5% to about 5%, all by weight of the vaginal care composition. It can be preferred to use silicone waxes that are solid or semisolid at room temperature but melt upon application to the body, especially the vaginal area which may be at a warmer temperature when occluded (for example under clothing) than typically exposed skin like the hands and face.
  • silicone waxes can leave a residue on the vaginal tissue, providing a preferred texture property due to the softening or melting during the application process. It is also believed that the silicone wax can provide a slick, coated feel to the vaginal tissue, which can alleviate pain caused by friction throughout the day.
  • the vaginal care composition may further comprise one or more emulsifiers.
  • emulsifiers can include cationic surfactants, anionic surfactants, non ionic surfactants, polyethylene glycol, polyethylene glycol, polypropylene copolymers, alkyl glucosides, ethoxylated fatty acids and, combinations thereof.
  • the vaginal care composition can comprise from about 0.005% to about 5% emulsifier, alternatively from about 0.01% to about 3%, alternatively from about 0.1% to about 1%, all by weight of the vaginal care composition.
  • the emulsifier can be polyethylene glycol (PEG) 100 stearate.
  • the vaginal care composition can comprise one or more thickeners.
  • the thickeners can be provided in amounts to facilitate achieving the desired viscosity in combination with the other ingredients.
  • the thickeners may be provided in an amount from about 0.5% to about 10%, alternatively from about 1% to about 8%, alternatively from about 1.5% to about 5%, all by weight of the vaginal care composition.
  • One advantage to including a thickener at this level is that it can help provide sufficient viscosity, allowing the vaginal care composition to be applied to a portion of the outer surface of a delivery device, such as an applicator, and administered to the vaginal introitus, and optionally external vaginal tissues.
  • the vaginal care composition may be difficult to apply to the delivery device and/or administer to the body, causing a mess on hands and countertops which may be unacceptable to consumers.
  • the vaginal care composition will remain on the vaginal tissue, thus providing longer lasting moisturizing benefits.
  • the vaginal care composition may dry too quickly after application, thus hindering the ability for the vaginal care composition to provide the desired vaginal health benefits.
  • the vaginal composition may be difficult to expel from packaging, be difficult to spread with minimal force, or may be difficult to wash or remove from the surface of the delivery device and/or hands.
  • vaginal care compositions herein it may be desirable to exclude from the vaginal care compositions herein thickeners and/or other materials that have hydroxyl or carboxyl functional moieties, which may impart undesirable feel properties (e.g., stickiness, heavy residue feel, non- lubricious feel) when applied to the labia and/or introitus. Accordingly, it may be desirable to formulate the vaginal care compositions herein to be substantially free of such materials.
  • mucoadhesive materials that may be undesirable for use herein include polyacrylates (e.g., Makimousse-2l and -25 brand sodium polyacrylate starch from Kobo), carbomers (e.g., Carbopol® from Lubrizol), polycarbophils (e.g., Noveon® from Lubrizol), poly(methylvinyl ether/maleic anhydride) copolymers, acidic synthetically modified natural polymers (e.g., carboxymethylcellulose), basic amine-bearing polymers (e.g., chitosan); acidic polymers obtainable from natural sources (e.g., alginic acid, pectin, tragacanth gum, and karaya gum); and neutral synthetic polymers (e.g., polyvinyl alcohol and polyvinylpyrrolidone) .
  • polyacrylates e.g., Makimousse-2l and -25 brand sodium polyacrylate starch from Kobo
  • carbomers e.g.
  • the thickener can be non-mucoadhesive.
  • the thickener can be selected from the group consisting of a polyacrylamide polymer, a fatty alcohol, and mixtures thereof.
  • the thickener can comprise a polyacrylamide polymer and a fatty alcohol.
  • “polyacrylamide polymer” refers to a polymer derived from at least one acrylamide, methacrylamide, alkyl acrylamide, or alkyl methacrylamide monomer.
  • the polyacrylamide polymer can be a homopolymer or copolymer and linear, branched, or cross- linked.
  • Suitable monomers for synthesizing polyacrylamide polymers can include acrylamide, methacrylamide, alkyl acrylamides, alkyl methacrylamides, anionic acrylamides, N- vinylpyrrolidone, and mixtures thereof. It can be preferred that the polyacrylamide polymer be synthesized from at least about 50 wt%, or at least about 70 wt%, or at least about 90 wt % acrylamide, methacrylamide, and mixtures thereof.
  • Alkyl acrylamide and alkyl methacrylamide are monomers in which the amide nitrogen is substituted with one Ci to C20 alkyl group or two Ci to Cx alkyl groups (preferably methyl, ethyl, or propyl), including N-methacrylamide, N-methylmethacrylamide, N- isopropylacrylamide, N-isopropylmethacrylamide, N-octyl acrylamide, N-tert-butyl acrylamide, N-phenyl acrylamide, N-sec-butyl acrylamide, N,N-dimethylmethacrylamide, and N,N-dimethylacrylamide.
  • Ci to C20 alkyl group or two Ci to Cx alkyl groups preferably methyl, ethyl, or propyl
  • the polyacrylamide polymer may be synthesized using from about 0 to about 25 wt% of an alkyl acrylamide or alkyl methacrylamide monomer, alternatively from about 0.1 to about 15 wt%, alternatively from about 0.5 to about 10 wt%.
  • Anionic acrylic monomers can include acrylamidoalkylsulfonic acids and salts thereof.
  • a preferred example is 2-Acrylamido-2-methylpropane sulfonic acid and salts thereof.
  • the polyacrylamide polymer may be synthesized using from about 0 to about 10 wt% of an acrylamidoalkylsulfonic acid monomer or salt thereof, alternatively from about 0.1 to about 5 wt%, alternatively from about 0.25 to about 2 wt%.
  • the polyacrylamide polymer can be synthesized with less than about 10 wt% acrylates, methacrylates, maleic anhydride, and/or vinyl acetate monomers, alternatively less than about 5 wt%, alternatively substantially free of the aforementioned monomers. It is more preferred for the polymer synthesis be free of acrylic acid and methacrylic acid monomers.
  • polymers with strong hydrogen bonding groups like -COOH, salts of -COOH, and -OH may cause the polymer to behave as a mucoadhesive.
  • Acrylic acid and methacrylic acid contain -COOH moieties and acrylates, methacrylates, maleic anhydride, and vinyl acetate monomers, when hydrolyzed, will also contain these hydrogen bonding moieties.
  • the polyacrylamide polymer may further comprise a cross-linking agent.
  • Suitable cross-linking agents are molecules with two or more, preferably two to four, vinyl moieties.
  • Suitable cross-linking agents can include N, N'-methylene-bisacrylamide, divinyl benzene, triallylamine, trimethallylamine, allyldimethallylamine, diallylmethallylamine, butadiene, 1,7- octadiene, allyl-acrylamides, allyl-methacrylamides, bisacrylamidoacetic acid, salts thereof, and mixtures thereof.
  • One preferred cross-linking agent is N, N'-methylenebisacrylamide.
  • the cross-linking agent can be present at a level of from about 25 to about 250,000 ppm, alternatively from about 50 to about 100,000 ppm, alternatively from about 100 to about 50,000 ppm.
  • the polyacrylamide polymer can have a weight average molecular weight of greater than about 1,000,000 g/mol, preferably greater than about 1,5000,000 g/mol, and can range up to about 30,000,000 g/mol.
  • Suitable polyacrylamide polymers can include Creagel® EZ 7 and Creagel® EZ PFC (available from The Innovation Company, Dreux Cedex, France), CustoPoly® E-5 and CustoPoly® 305 (available from Custom Ingredients, Inc., San Clemente, CA), Endicare® ETP305 and Endicare® ETP505 (available from Coast Southwest Inc., Placentia, CA), FlocareTM T 920 GC from SNF S.A.S. (France), HallGelTM 305 from The Hallstar Company (Chicago, IL), and SepigelTM 305 and SepigelTM 501 from Seppic Corporation (Fairfield, N.J.).
  • polyacrylamide polymers Most preferred among these polyacrylamide polymers is the polymer given the CTFA designation polyacrylamide and isoparaffin and laureth-7, available under the Tradename SepigelTM 305 from Seppic Corporation, which is synthesized using acrylamide, 2- Acrylamido-2-methylpropane sulfonic acid and cross-linked with N,N- methylenebisacrylamide.
  • the thickener can comprise a fatty alcohol.
  • fatty alcohols can have a melting temperature of greater than 30°C, alternatively greater than about 37°C, alternatively greater than about 50°C.
  • the melting temperature of the fatty alcohols can be measured according to the drop melting point method of ASTM D127 (January 1, 2015).
  • Non-limiting examples of fatty alcohols can include stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, paimitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
  • the vaginal care composition can comprise a fatty alcohol selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (steareth-2), the polyethylene glycol ether of cetyl alcohol having an average of about 2 ethylene oxide units, and mixtures thereof.
  • the vaginal care composition can comprise a fatty alcohol selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol and mixtures thereof.
  • the fatty alcohol can be selected from the group consisting of saturated C 1 ⁇ 2 to C30 fatty alcohols, saturated C 1 ⁇ 2 to C30 ethoxylated fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated Ci 6 to C30 diols, saturated Ci 6 to C30 monoglycerol ethers, saturated Ci 6 to C30 hydroxy fatty acids, and mixtures thereof, having a melting temperature of at least about 45° C.
  • the vaginal care composition can comprise a mixture of two or more fatty alcohols.
  • the vaginal care composition can comprise from about 0.1% to about 5% of a fatty alcohol, alternatively from about 0.5% to about 2.5%, alternatively from about 0.75% to about 2%, all by weight of the vaginal care composition.
  • these fatty alcohols can help in the formation of the rheological characteristics of the composition which can contribute to the physical stability of the composition. It is believed that the fatty alcohol can increase the viscosity of the vaginal care composition at room temperature, allowing the vaginal care composition to be applied to a delivery device and administered to the body.
  • a selection of a low level of hyaluronic acid and a polyacrylamide thickener can provide an oil-in-water emulsion vaginal care composition that is stable and provides the lubrication and vaginal health benefits without the undesirable sticky feel.
  • the vaginal care composition may be substantially free of retinol, retinyl esters, retinaldehyde, peptides, ethanol, sunscreens, parabens, and/or sensates such as warming or cooling agents.
  • the vaginal care composition may be substantially free of perfumes, flavorants, and/or pigments.
  • the vaginal care composition may be substantially free of an estrogen agent and/or a progesterone agent.
  • the vaginal care composition may be substantially free of particulates for exfoliation. In such examples, the excluded particulates have an average particle size of from about 125 microns to about 700 microns or more.
  • Such particulates may include polyethylene terephthalate (PET) microbeads, crushed apricot kernel shells, salt crystals, sugar crystals, and crushed volcanic rock. It is believed the foregoing ingredients may either be irritating or present an unsatisfactory user experience in a vaginal care composition.
  • the vaginal care composition may be substantially free of the combination of carbomer and carbophil and other bioadhesives or mucoadhesive ingredients.
  • the vaginal care composition may preferably have a viscosity suitable for dispensing the composition without dripping or runniness as the user spreads the vaginal care composition about the vaginal introitus and/or external vaginal tissues.
  • the vaginal care composition may also have a viscosity conducive to spreading onto the vaginal tissues of interest using a delivery device without undue effort.
  • the vaginal care composition may exhibit a viscosity of from about 2,000cps to about 200,000cps, alternatively from about 5,000cps to about l50,000cps, alternatively from about 20,000cps to about 90,000cps, or any integer value from about 2,000 cps to about 200,000cps, or any range formed by any of the preceding values.
  • the vaginal care composition can have a viscosity of from about 20,000cps to about 200,000cps, alternatively from about 40,000cps to about 100,000 cps, alternatively from about 55,000cps to about 80,000cps.
  • the viscosity of the vaginal care composition can be measured according to the Viscosity Test Method described hereinafter.
  • any given material may serve multiple purposes within the vaginal care composition formulation.
  • polyethylene glycol can be used as a humectant and/or an emulsifier.
  • Emulgade® PL68/50 from BASF (Cincinnati, OH).
  • CF600 from Momentive Performance Materials (Waterford, NY).
  • Aqueous Phase (A) is prepared by combining all ingredients in a beaker or pot and heating to about 70°C to 80°C while stirring with an overhead mixer.
  • Oil Phase (B) is prepared in a separate beaker or pot with a magnetic stir bar by combining all ingredients in Oil Phase (B) and heating to about 70°C to 80°C while stirring with a magnetic stir plate.
  • Aqueous Phase (C) is prepared in yet another beaker or pot with a magnetic stir bar by combining all ingredients and heating to 40 °C while stirring with a magnetic stir plate.
  • Oil Phase (B) reaches about 70°C to 80°C, it is poured into the Aqueous Phase (A) and is milled with a Tekmar mill for 5 minutes at about 5,000 rpm to 10,000 rpm, creating an oil-in-water emulsion. After milling, the heat is turned off and the mixture is allowed to cool while stirring with an overhead mixer. When the mixture reaches 60°C, SepigelTM 305 is added with continuous stirring using an overhead mixer. When the mixture reaches 50°C the Acidic Aqueous Phase (C) is added with continuous stirring using an overhead mixer.
  • the vaginal care compositions herein may be applied by any suitable means known for applying such products, including digitally (i.e., with the hands and/or fingers) and/or with a disposable or reusable delivery device.
  • the user may dispense the vaginal care composition onto a finger, hand, and/or delivery device and then apply the vaginal care composition to the target vaginal tissue. Additionally or alternatively, the user may dispense the vaginal care composition directly onto the target vaginal tissue and use a finger, hand, and/or delivery device to spread the vaginal care composition.
  • Dispensing a vaginal care composition may include pouring, dipping, squeezing, and/or spraying from a container (e.g. tube, jar, bottle, spray bottle, aerosol).
  • Non-limiting example of delivery devices for applying a vaginal care composition can include gloves, swabs, wipes, sponges, plunger-type devices, and applicators. In one aspect, it may be preferred to use a delivery device to deliver the vaginal care composition because it can help keep the vaginal care composition from touching the user’ s hands.
  • a preferred delivery device for use in applying the vaginal care composition to the vaginal introitus and/or the external vaginal tissue is the egg-shaped applicator described hereinafter.
  • the applicator can be packaged together with a vaginal care composition as a kit and sold as a packaged unit. Alternatively, the elements may be provided separately.
  • kit 110 can comprise applicator 100 comprising an elongate body having a proximal end 114 and an insertion portion 116 comprising tip 124 opposite proximal end 114. Applicator 100 can also comprise grippable portion 118 adjacent to proximal end 114. Kit 110 can comprise a single applicator that is reusable or a plurality of applicators may be provided. Kit 110 may further comprise dispenser 104 or receptacle (not shown). Dispenser 104 can comprise reservoir 142, in which the vaginal care composition can be stored, and a hand pump 144 for drawing the vaginal care composition from the reservoir and dispensing a dosage of the vaginal care composition from dispenser 104. Alternatively, the vaginal care composition can be stored in a chamber within applicator 100 (not shown). Kit 110 may further comprise pouch 106, in which applicator 100 and/or dispenser 104 may be stored before and after use.
  • Insertion portion 116 may be shaped and sized to accommodate the anatomical geometry of the vaginal introitus and for applying the vaginal care composition thereto. Insertion portion 116 can terminate at a longitudinal distance L2 from tip 124, where the point of termination is referred to herein as base 125 of insertion portion 116. While the insertion portion may be described herein as terminating at the base for purposes of discussion, the base is not necessarily a distinct physical structure (although in some examples it may be) but rather a location along a longitudinal axis A defined by the length L2. In one aspect, insertion portion 116 may have a generally circular cross-section at base 125.
  • Insertion portion 116 is preferably rotationally symmetrical about the longitudinal axis A, as this symmetry may facilitate easier usage and application of a vaginal care composition by a female user.
  • insertion portion 116 has an overall shape that looks the same after an angular rotation thru a partial turn of 45°, 90°, 135°, 180°, 225°, 270°, or 315° about its longitudinal axis.
  • the insertion portion can be cone-shaped.
  • Tip 124 of insertion portion 116 may have any shape, including but not limited to rounded, concave, convex, flat, indented, angled or pointed. While the insertion portion may be provided in a variety of shapes, in some examples, the insertion portion has a continual taper, has a rounded tip, a substantially circular cross section at the base and a side or lateral surface that is slightly convex from the base to the rounded tip.
  • the lateral, outer surface (e.g., 120 in FIG. 3) of insertion portion 116 may be substantially smooth so as to avoid irritation of the vaginal tissues during manipulation of the applicator to administer the vaginal care composition to the vaginal tissues of interest.
  • the dimensions and structural attributes of insertion portion 116 may facilitate its use within the vaginal areas described above. While there may be considerable variability in vaginal shape, axis, and dimension from woman to woman, the dimensions and structural attributes of the insertion portion may be designed to accommodate the vaginal introitus, taking into consideration a wide range of anatomical measurements while also self-limiting the insertion depth of the applicator. Since the applicators may be used by women suffering from vaginal atrophy, the size and shape should also accommodate the anatomical changes that occur with vaginal atrophy.
  • the length L2 of insertion portion 116, taken along the longitudinal axis A may be from about 10mm to about 25mm, alternatively from about 10mm to about 20mm.
  • the width of base 125 may also be the maximum width of insertion portion 116 in order to limit the distance applicator 100 is inserted into the vaginal introitus using gentle hand pressure (and without experiencing discomfort) and/or to signal to a user that the appropriate insertion depth has been achieved during use.
  • insertion portion 116 or another portion of the body may further exhibit dimensions that provide a self-limiting feature with respect to insertion beyond the lower region of the vagina, such that in some examples, contact between insertion portion 116 and either of a middle region or an upper region of the vagina, including the cervix, is avoided.
  • Applicator 100 may also comprise grippable portion 118 adjacent proximal end 114.
  • the grippable portion may be defined by a texture or visual indicator.
  • the texture may comprise a plurality of protrusions, a plurality of recesses, and combinations thereof.
  • the texture may be provided as a plurality of ridges, a plurality of grooves, and combinations of the foregoing.
  • the grippable portion may alternatively or in addition thereto be provided with a surface finish (e.g., micro-texture) or surface treatment (e.g., dip coating, spray coating, printing) that enhances the grippability of the grippable portion.
  • the texture, surface finish, or surface treatment may partially or wholly encircle the body.
  • the texture may be provided as a repeating, preferably regularly repeating, pattern, although random or irregular patterns may also be provided. Further, the texture may be provided in the shape of objects, some non limiting examples being leaves, flowers, stars, and geometric shapes. The texture may also be provided as a repeating, closed geometric shape, some non- limiting examples being circles, diamonds, triangles, rectangles, and combinations thereof. The texture, surface finish, or surface treatment may extend about 10mm or more from the proximal end of the applicator.
  • Proximal end 114 may be substantially flat. As shown for example in FIG.3, proximal end 114 of applicator 100 includes a flat portion or bottom which can allow a user to stand the applicator 100 in an upright position on a surface before and after use, such that it can be oriented in a way to minimize or prevent contact between a resting surface and the insertion portion of the applicator 100.
  • the overall length of applicator 100 may minimize or prevent contact between a female user’s fingers and the vaginal areas described above while providing for an appropriate insertion depth slightly beyond the vaginal introitus.
  • the length of the applicator may be from about 35mm to about 85mm, alternatively from about 40mm to about 70mm, alternatively from about 45mm to about 65mm, alternatively any integer value from about 35mm to about 85mm or any range formed by any of the preceding values.
  • the applicator can be provided in a variety of overall shapes, it can be preferred that the applicator is substantially ovoidal, or egg-shaped in profile and rotationally symmetrical thru 360° of angular rotation about the longitudinal axis A thereof. It is believed this geometric shape can be desirable for application of a spreadable vaginal care composition to the vaginal introitus and optionally the vulva, vestibule, labia majora, labia minora, and/or external urogenital tract. This shape may also be particularly useful in the case of women suffering from vaginal atrophy, given the variability in shape and size of this vaginal tissue between users as well as the sensitivity of these tissues. It is also believed that this shape can facilitate grasping and manipulating the applicator by a user to apply the vaginal care composition easily while in a variety of positions (e.g., seated, standing or laying down) and without viewing the tissues of interest during use.
  • positions e.g., seated, standing or laying down
  • the applicators may be devoid of moving parts, electrically powered elements (e.g., motors, lights, circuits, buzzers, speakers, etc.) and/or electrical power sources (e.g., batteries) to provide an applicator that is simple to manufacture and also easily immersed in or rinsed with water for cleaning.
  • An applicator that is devoid of batteries and/or electrically powered elements (e.g., motors, lights, etc.) is referred to as a non-electrical applicator.
  • At least 60%, 70%, 80%, 90%, 95% or 100% of the bulk volume can be solid volume.
  • the body may be devoid of chambers for storing a flowable composition and/or passages, conduits, channels and/or openings or ports for delivering such a composition to an outer surface thereof.
  • the applicator can comprise a chamber for storing a flowable composition and/or passages, conduits, channels and/or openings or ports for delivering such a composition to the outer surface thereof (e.g., the insertion portion or its tip).
  • the applicator can comprise a chamber in fluid communication with an opening defined on the insertion portion or tip.
  • the body may be devoid of plungers and other structures that may be used to expel a vaginal care composition from the body of the applicator.
  • the applicator can comprise a plunger or other structure that can be used to expel a vaginal care composition from the body of the applicator.
  • the body of the applicator is not phallic shaped.
  • the applicator and/or the materials used to form the applicator may exhibit one or more properties suitable for applying a vaginal care composition to the vaginal introitus and, optionally, the external vaginal tissue, some of which may be more delicate, sensitive, or fragile in women with vaginal atrophy.
  • the applicator and/or the materials used to form the applicator may also be facilitate the grippability, re-usability, and cleanliness of the applicator.
  • suitable materials can include one or more of a thermoplastic elastomer, a natural rubber, a synthetic rubber (e.g., a silicone elastomer/silicone rubber), a polyester (e.g., a polyurethane, such as STERALLOY® 2021-5 available from Hapco, Inc.) and/or a thermoplastic olefin.
  • a thermoplastic elastomer e.g., a natural rubber, a synthetic rubber (e.g., a silicone elastomer/silicone rubber), a polyester (e.g., a polyurethane, such as STERALLOY® 2021-5 available from Hapco, Inc.) and/or a thermoplastic olefin.
  • the applicator may further comprise one or more visual indicators to indicate to the user, for example, where to hold the applicator, which end of the applicator is“up” or“down”, and/or which surfaces of the applicator to which the vaginal care composition should be applied.
  • the visual indicator can comprise colors, micro-textures, patterns, text, graphics, coatings, and combinations thereof.
  • the visual indicator can be a dosing indicator that visually indicates to a user the surface of the body onto which the vaginal care composition is applied or an insertion indicator that visually indicates to user how far the body should be inserted into the vaginal introitus.
  • the dosing indicator and/or the insertion indicator may form part of the insertion portion.
  • the dosing indicator is visually distinct from the insertion indicator.
  • the dosing indicator may be provided in the form of a first color while the insertion indicator might be provided as a second color different from the first color.
  • the dosing indicator and the insertion indicator can be the same visual indicator.
  • the visual indicators may be printed on the body, in molded with the body or be in the form of a coating applied to the body.
  • the vaginal care composition may be stored within a dispenser or a receptacle (not shown).
  • the receptacle may be any of a jar, a bowl, a cup, or any of a variety of suitable receptacles, which may employ a screw-on lid or closure.
  • the insertion portion can be dipped into the receptacle to contact the vaginal care composition to transfer the vaginal care composition to a surface of the applicator.
  • the applicator and the dispenser storing the vaginal care composition may be packaged together as a unit for sale to a consumer.
  • Some suitable packages may include boxes, cartons, and clamshell packages formed from plastic and/or a paper material.
  • the kit may further include a container, such as, for example, a drawstring pouch or bag (e.g., 106), for storing one or more of the applicator and, optionally, the dispenser in between uses by a consumer.
  • a container may be any of a variety of suitable containers or cases for storing one or more items associated with a kit.
  • the container may facilitate hygiene by maintaining cleanliness of the applicator between uses.
  • a particularly suitable applicator is further described in U.S. Provisional Patent Application No. 62/622,298 filed on January 26, 2018, which is herein incorporated by reference in its entirety.
  • kits, delivery devices, and vaginal care compositions may be used in a variety of ways.
  • the vaginal care composition can be administered to reduce the feeling of vaginal dryness.
  • the vaginal care composition can be administered to restore vaginal moisture and lubrication.
  • vaginal health benefit comprising administering the vaginal care composition to the vaginal introitus and, optionally, external vaginal tissues such the vulva, vestibule, labia majora, labia minora, or external urogenital tract.
  • the one or more vaginal health benefit can be selected from the group consisting of providing natural moisture; reducing vaginal irritation and/or burning; providing natural lubrication; soothing vaginal dryness; replenishing vaginal moisture; supplementing the body’s natural lubrication; providing all day vaginal moisture and/or lubrication; reducing pain during sex; relieving the discomfort associated with vaginal dryness; and combinations thereof.
  • vaginal dryness While a method of reducing the feeling of vaginal dryness is exemplified, it should be understood that the methods described herein can also be used to restore vaginal moisture and lubrication, to provide one or more vaginal health benefit, to treat vaginal dryness, and/or to treat vaginal atrophy.
  • the method for reducing the feeling of vaginal dryness can include a female user grasping the delivery device, depositing an amount of a vaginal care composition on at least a portion the delivery device, manipulating the delivery device to administer the vaginal care composition to her vaginal introitus and, optionally, one or more of the vulva, vestibule, labia majora, labia minora, or external urogenital tract, with the delivery device such that at least a portion of the vaginal care composition thereon is transferred to the vaginal tissues of interest.
  • the method for reducing the feeling of vaginal dryness can include a female user grasping the delivery device and manipulating the delivery device to administer the vaginal care composition to her vaginal area.
  • the method for reducing the feeling of vaginal dryness can include a female user holding or grasping an applicator and applying an amount of the vaginal care composition to at least a portion of the insertion portion, preferably the dosing surface, of the applicator, manipulating the applicator to administer the vaginal care composition to her vaginal introitus and, optionally, external vaginal tissues, with the applicator such that at least a portion of the vaginal care composition thereon is transferred to the vaginal tissues of interest.
  • the female user may use those indicators as a guide as to where to deposit the vaginal care composition on the applicator (e.g., the dosing surface) or how far to insert the body into her vaginal introitus during use.
  • the dosing indicator may provide both visual cues to the female user (i.e., the same visual indicator functions as both a dosing indicator and an insertion indicator for the female user).
  • the method may further include dispensing the vaginal care composition from the dispenser 104.
  • the vaginal care composition may be dispensed onto the insertion portion.
  • the dispenser 104 may regulate an amount of the vaginal care composition released therefrom.
  • the amount of the vaginal care composition released by the dispenser 104 may be the single dose sufficient for covering the insertion portion or a lesser amount such that multiple actuations (e.g., 2-4) of the dispenser are needed to provide a suitable amount.
  • the method can include the female user dispensing the vaginal care composition from a chamber within the applicator, for example by squeezing or using a plunger or pump, such that the vaginal care composition is provided on at least a portion of the external surface of the applicator.
  • the vaginal care composition can be stored within a receptacle (not shown), such as ajar or can.
  • the insertion portion can be dipped into the receptacle to contact the vaginal care composition for application thereon.
  • a method for reducing the feeling of vaginal dryness may include applying a vaginal care composition to at least one digit (e.g., finger or thumb) of a female user and administering the vaginal care composition to the vaginal introitus and, optionally, the external vaginal tissue using her at least one digit.
  • the amount of vaginal care composition applied to the insertion portion surface may be enough to cover the insertion portion surface but not so much that dripping of the vaginal composition from the insertion portion is induced.
  • the amount of the vaginal care composition applied to the insertion portion can be from about O.lg to about 2g, alternatively from about 0.2g to about l.5g, alternatively from about 0.5g to about lg.
  • the female user may manipulate the applicator in variety manners.
  • the female user may insert the insertion portion into her vaginal introitus using gentle handle pressure (e.g., until slight resistance to insertion is noticed by the user) so as to not over insert the body thru the vaginal introitus.
  • the body of the applicator is preferably only inserted far enough to treat the vaginal introitus without discomfort.
  • the insertion portion is inserted only so far as is comfortable to avoid pain or tearing or bleeding from the delicate tissues.
  • the female user may insert the body into the vaginal introitus a distance of 40mm, 35mm, 30mm, 25mm or less, or from about 30mm to about 5mm, or from about 25mm to about 10mm.
  • the tip of the insertion portion is not inserted as far as the middle or upper region of the vaginal canal by the female user. In some examples, the tip of the insertion portion is inserted no further than the lower region of the vaginal canal. It is believed that at least some female users may find this method less intimidating and/or more simple and convenient, thereby encouraging long term habit adoption and compliance.
  • the body of the applicator may then be retracted to administer any remaining vaginal care composition thereon (and/or to spread some of the vaginal care composition applied to the vaginal introitus) to the external vaginal tissues, such as labia minora, labia majora, the clitoris, the perineum, the urogenital tract, etc.
  • the female user may manipulate the applicator by inserting the body into the vaginal introitus and rotating the body of the applicator using her wrist, retracting the body from the vaginal introitus and then swiping the body along the external vaginal tissues.
  • the female user may administer the vaginal care composition to the vaginal tissues of interest for a period of time from about 1 second to about 40 seconds, or about 1 second to about 30 seconds, or from about 1 second to about 15 seconds, or any range formed by any of the preceding values.
  • a short administration time is desirable for providing a method that is convenient and quick to complete.
  • the female user may use the applicator to apply the vaginal care composition on a regular basis versus as a mere precursor to sexual intercourse.
  • the method of use may not be immediately followed by sexual intercourse.
  • sexual intercourse may not even occur within 6, 12 or 24 hours of the administration of the vaginal care composition since application of the vaginal care composition is not necessarily linked to the timing of sexual intimacy.
  • the method may be performed by a female user at least twice per week or three, four, five, six times per week or more for a period of at least 4 weeks or 8 weeks or 12 weeks or more. In other instances, the method may be performed daily for a period of at least 4 weeks or 8 weeks or 12 weeks or more. In some instances, the female user may perform the method for 6, 8, 10, 12 months or more. The method may be performed by a female user at about the same time each day or following a daily ritual activity in order to facilitate habit adoption and habit compliance. For example, the female user may perform the method in the morning, as part of a routine (e.g., after showering). Similarly, a female user may perform the method in the evening before bed or at any other time convenient to the female user. Alternatively, the method may be performed multiple times per day or as needed.
  • the methods may further include cleaning the applicator so that the applicator may be reused at a later time to repeat administration of the vaginal care composition.
  • the applicator may be rinsed, sprayed or immersed in a liquid and/or wiped with a substrate to remove any residual vaginal care composition or bodily fluids.
  • the cleaning liquid may comprise water and, optionally, one or more adjuncts such as, for example, a soap or other surfactant.
  • the applicator may be immersed in a container containing the cleaning liquid or merely rinsed or immersed in tap water, for example.
  • the applicator may be dried with a substrate or appliance (e.g., hair dryer) or left to air dry, and the applicator stored in a protective in a reusable container/package (e.g., the drawstring pouch shown in FIG. 1) for cleanliness until the next use.
  • the cleaning step may be performed prior to application of the vaginal care composition to the applicator, subsequent to administration of the vaginal care composition to desired vaginal tissue, or both.
  • the applicator may be disposable or intended for a single use.
  • vaginal dryness or irritation may also be due to, for example, vaginitis, inflammation of the vaginal tissue due to thinning and shrinking of the tissues, sexual arousal disorder, menopause, drug (prescription or over the counter) induced vaginal dryness, dyspareunia, sexual pain disorder, pregnancy, breast feeding, hormone imbalance, anxiety, and diabetes.
  • the kits and vaginal care compositions may have non- medical uses for females in need of vaginal lubrication.
  • Vaginal atrophy (sometimes referred to as atrophic vaginitis or vaginitis, vulvovaginal atrophy, or urogenital atrophy) may be characterized by thinning and shrinking of tissues as well as decreased lubrication, typically induced by a reduction in estrogen which happens naturally in perimenopausal, menopausal and post menopausal women. Symptoms may include vaginal soreness, itching, dryness, and painful intercourse.
  • the female user is 30, 40, 45, 50, or 55 years of age or older, experiencing a reduction in estrogen levels, suffering from vaginal atrophy, vaginal dryness, has undergone a hysterectomy, and/or is perimenopausal, menopausal or post-menopausal. It is believed that performance of the methods described herein using an applicator and vaginal care composition may provide the female user with an acute and/or a chronic reduction in one or more of vaginal dryness, pain during sexual intercourse, vaginal itching, and vaginal irritation.
  • the viscosity of samples is measured using Brookfield RV viscometer fitted with a helipath T-bar spindle type T-C.
  • the viscometer is leveled, set up, and calibrated according to the manufacturer’s standards.
  • the viscometer speed (RPM) is selected to ensure the measured viscosity is within the manufactures recommended settings.
  • Samples are stored in sealed glass jars with an opening and internal diameter of at least 40mm and filled to a height of at least 50mm with care taken to avoid entrapped air bubbles. Centrifugation may be used to help remove entrained air. Sample jars are equilibrated at 23°C + 2°C and about 50% + 2°C relative humidity for at least 24 hours prior to measurement.
  • Viscosity is measured at 23°C + 2°C and about 50% + 2% relative humidity by placing the uncapped sample jar under the viscometer and lowering the viscometer until the tip of the t-bar touches the surface of the sample. The descending helipath is turned on and a timer started once the cross-bar of the t-bar touches the surface of the sample. For 1 minute, a reading is taken every 10 seconds. The viscosity is the arithmetic average of the viscosities recorded. Care is taken to ensure the t-bar does not touch the glass jar.
  • a composition comprising an oil-in-water emulsion, a thickener comprising a polyacrylamide polymer and a fatty alcohol, and optionally hyaluronic acid or a salt thereof, wherein the composition preferably has a pH of from 4 to 5.5, more preferably from 4.3 to 5.0, for use in the treatment of vaginal dryness.
  • composition according to paragraph A for use in the treatment of vaginal dryness wherein the composition comprises from about 0.1% to about 2% hyaluronic acid or salt thereof, by weight of the composition.
  • composition for use in the treatment of vaginal dryness, wherein the composition comprises from 0.5% to 10% of the thickener, by weight of the composition, preferably from 1% to 8%, more preferably from 1.5% to 5%.
  • composition according to any of the preceding paragraphs for use in the treatment of vaginal dryness wherein the composition further comprises a preservative system comprising a preservative and a preservative enhancing agent comprising sorbitan caprylate, preferably the preservative comprises an organic acid preservative and a salt of the organic acid preservative.
  • composition according to any of the preceding paragraphs for use in the treatment of vaginal dryness wherein the composition further comprises from 0.05% to 5% of an emollient, wherein the emollient is preferably a botanical oil.
  • composition comprising an oil-in-water emulsion, a thickener comprising a polyacrylamide polymer and a fatty alcohol, and optionally hyaluronic acid or a salt thereof, wherein the composition preferably has a pH of from 4.0 to 5.5, more preferably from 4.3 to 5.0, as a vaginal care composition for restoring vaginal moisture and/or lubrication.
  • composition comprises from 0.1% to 2% hyaluronic acid or salt thereof, by weight of the composition.
  • composition comprises from 0.5% to 10% of the thickener, by weight of the composition, preferably from 1% to 8%, more preferably from 1.5% to 5%.
  • composition further comprises a preservative system comprising a preservative and a preservative enhancing agent comprising sorbitan caprylate, preferably the preservative comprises an organic acid preservative and a salt of the organic acid preservative.
  • composition further comprises from 0.05% to 5% of an emollient, wherein the emollient is preferably a botanical oil.
  • a method of reducing the feeling of vaginal dryness comprising the step of administering a vaginal care composition to the vaginal area of a female user in need thereof; wherein the vaginal care composition comprises an oil-in-water emulsion, a thickener comprising a polyacrylamide polymer and a fatty alcohol, and optionally hyaluronic acid or a salt thereof, wherein the composition preferably has a pH of from 4.0 to 5.5, more preferably from 4.3 to 5.0.
  • the method according paragraph K comprising the following steps: providing an amount of the vaginal care composition to at least a portion of an outer surface of an applicator, and administering at least a portion of the amount of the vaginal care composition to the vaginal introitus and, optionally, one or more of the vulva, vestibule, labia majora, labia minora, and/or external urogenital tract while grasping and manipulating the applicator, preferably inserting a portion of the applicator into the vaginal introitus a distance of about 35 mm or less.
  • a kit for reducing the feeling of vaginal dryness comprising:
  • an applicator for reducing the feeling of vaginal dryness comprising a non electrical, elongate body comprising a tapered insertion portion having a tip, a proximal end opposite the insertion portion, a dosing indicator delineating a dosing surface, and a grippable portion adjacent the proximal end; and a. a vaginal care composition comprising an oil-in-water emulsion, a thickener comprising a polyacrylamide polymer and a fatty alcohol, and optionally hyaluronic acid or a salt thereof, wherein the composition preferably has a pH of from 4.0 to 5.5, more preferably from 4.3 to 5.0.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de réduction de la sensation de sécheresse vaginale. Le procédé comprend la fourniture à une utilisatrice d'une composition de soin vaginal sur au moins une partie de la surface extérieure d'un applicateur et l'administration d'au moins une partie de la quantité de la composition de soin vaginal à son introïtus vaginal et, facultativement, à un ou plusieurs de ses vulve, vestibule, grandes lèvres, petites lèvres, ou tractus urogénital externe tout en saisissant et en manipulant l'applicateur. La composition de soin vaginal peut comprendre une émulsion huile dans l'eau et un épaississant comprenant un polymère polyacrylamide et un alcool gras.
PCT/US2019/015051 2018-01-26 2019-01-25 Procédés et compositions pour réduire la sensation de sécheresse vaginale WO2019147877A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP19706817.4A EP3743044A1 (fr) 2018-01-26 2019-01-25 Procédés et compositions pour réduire la sensation de sécheresse vaginale
CN201980009752.5A CN111655232A (zh) 2018-01-26 2019-01-25 用于减轻阴道干燥感的方法和组合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862622298P 2018-01-26 2018-01-26
US62/622,298 2018-01-26
US201862666741P 2018-05-04 2018-05-04
US62/666,741 2018-05-04

Publications (1)

Publication Number Publication Date
WO2019147877A1 true WO2019147877A1 (fr) 2019-08-01

Family

ID=65516754

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2019/015049 WO2019147875A1 (fr) 2018-01-26 2019-01-25 Procédés et compositions pour réduire la sensation de sécheresse vaginale
PCT/US2019/015051 WO2019147877A1 (fr) 2018-01-26 2019-01-25 Procédés et compositions pour réduire la sensation de sécheresse vaginale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2019/015049 WO2019147875A1 (fr) 2018-01-26 2019-01-25 Procédés et compositions pour réduire la sensation de sécheresse vaginale

Country Status (3)

Country Link
EP (2) EP3743046A1 (fr)
CN (2) CN111655234A (fr)
WO (2) WO2019147875A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020006191A1 (fr) * 2018-06-29 2020-01-02 The Procter & Gamble Company Compositions pour soins vaginaux
WO2021160049A1 (fr) * 2020-02-12 2021-08-19 深圳优丽康生物技术有限公司 Composition bactériostatique, son procédé de préparation et son utilisation
CN112773737A (zh) * 2021-02-07 2021-05-11 北京健翔嘉业日用品有限责任公司 一种护肤抑菌椰脂溶剂及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038140A2 (fr) * 2006-06-07 2008-04-03 Foamix Ltd. Vecteur expansible à base de polypropylène glycol et compositions pharmaceutiques associées
US20140178314A1 (en) * 2012-12-19 2014-06-26 The Procter & Gamble Company Compositions and/or articles with improved solubility of a solid active
US20150190425A1 (en) * 2009-04-15 2015-07-09 Bmg Pharma Llc Mineral salt-sulfonic acid compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20060122A1 (it) * 2006-01-25 2007-07-26 Polichem Sa Composizioni per uso vaginale
DE102009022444A1 (de) * 2009-05-23 2010-01-07 Clariant International Limited Zusammensetzung enthaltend Sorbitanmonocaprylat und antimikrobielle Wirkstoffe
DE102009022445A1 (de) * 2009-05-23 2009-12-24 Clariant International Limited Zusammensetzung enthaltend Sorbitanmonocaprylat und Alkohol
CA2817713C (fr) * 2010-11-12 2018-12-04 The University Of Utah Research Foundation Dispositifs intravaginaux pour l'administration regulee de lubrifiants
EP2739148B1 (fr) * 2011-08-04 2016-09-28 Clariant International Ltd Compositions comprenant du monoester d'isosorbide et des diols aliphatiques vicinals
US9814675B2 (en) * 2016-02-23 2017-11-14 Elle Pharmaceutical, LLC Aqueous gel composition and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038140A2 (fr) * 2006-06-07 2008-04-03 Foamix Ltd. Vecteur expansible à base de polypropylène glycol et compositions pharmaceutiques associées
US20150190425A1 (en) * 2009-04-15 2015-07-09 Bmg Pharma Llc Mineral salt-sulfonic acid compositions and methods of use
US20140178314A1 (en) * 2012-12-19 2014-06-26 The Procter & Gamble Company Compositions and/or articles with improved solubility of a solid active

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"STERALLOYO 2021-5", HAPCO, INC.
ASTM D127, 1 January 2015 (2015-01-01)

Also Published As

Publication number Publication date
EP3743044A1 (fr) 2020-12-02
CN111655232A (zh) 2020-09-11
CN111655234A (zh) 2020-09-11
WO2019147875A1 (fr) 2019-08-01
EP3743046A1 (fr) 2020-12-02

Similar Documents

Publication Publication Date Title
WO2019147877A1 (fr) Procédés et compositions pour réduire la sensation de sécheresse vaginale
MX2013014884A (es) Sistema aplicador para la aplicacion de un liquido viscoso a la piel humana.
JP2022126708A (ja) 膣の乾燥を治療するためのアプリケータ
US20200297622A1 (en) Methods And Compositions For Reducing The Feeling Of Vaginal Dryness
US20200297630A1 (en) Methods And Compositions For Reducing The Feeling Of Vaginal Dryness
EP3743047A1 (fr) Procédés et compositions pour réduire la sensation de sécheresse vaginale
CA2759213C (fr) Bande jetable a usage unique pour application de compositions topiques
US11590073B2 (en) Methods and compositions for reducing the feeling of vaginal dryness
EP3801731B1 (fr) Applicateurs pour le traitement d'affections vaginales
CN112135621A (zh) 用于治疗阴道萎缩的组合物和方法
US11633452B2 (en) Compositions and methods for treating vaginal dryness
US20210016069A1 (en) Applicators for treating vaginal dryness
US20210322740A1 (en) Methods and applicators for treating vaginal conditions
WO2007124342A2 (fr) Dispositif d'administration d'agent hygiénique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19706817

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019706817

Country of ref document: EP

Effective date: 20200826